Integrichain Blog

Blog

Contracts & Pricing Marta Rutherford Michael Gorokhovsky
June 27, 2022

Pharma vs. 340B

4 Minute Read

This month’s market update features the latest news detailing the tumultuous relationship between pharma and 340B, including The Supreme Court, HRSA, and insight on how inflation escalates everything.

pharmaceutical pricing strategy reporting

Contracts & Pricing Jeff Baab
June 14, 2022

Top Trends in Contracting

6 Minute Read

Using exclusive ICyte Benchmarks from over 230 brands across more than 50 manufacturers, we examine the top trends in specialty pharmacy contracting.

orphan drug

Launch Readiness Dave Weiss
June 7, 2022

Best Practices: Identifying and Avoiding Patient Access Barriers

4 Minute Read

Market access leaders from DBV Technologies, Sesen Bio, and Karyopharm Therapeutics discuss strategies to overcome obstacles to patient initiation and adherence.

Capitol Building, where state price transparency laws are enacted

Government Pricing Stephanie Trunk John Whitridge
May 26, 2022

The Nuance and Necessity of Timely State Price Transparency Reporting

4 Minute Read

Expert opinions from a recent price transparency congress on reporting, remediation, and ways to manage state price transparency now and in the future.

Contracts & Pricing Darren Schneider Rupal Patel
May 22, 2022

CMS Medicaid Copay Ruling

4 Minute Read

And other industry updates including the Medi-Cal older adult expansion and profiles of new pharmacy models and 3PLs entering the market.

Pharmaceutical distribution channel analytics

Contracts & Pricing Matt Cunningham
April 28, 2022

Regulatory Market Updates, April 2022

3 Minute Read

We recap pressing issues from the past month, including the DUNS number transition, the latest in the Eli Lilly/Streck case, and rising healthcare spending for U.S. payers.

Maze representing the challenges faced with pharmaceutical market access

Market Access Blogs Michael Kerman
April 19, 2022

The Top 10 Market Access Challenges

5 Minute Read

We explore the 10 most common challenges facing Market Access operations, based on over 15 years of experience with more than 250 pharma manufacturers.

Three Pharma regulatory consultants working at a table and planning their pharma gross-to-net strategy

Contracts & Pricing Jeff Baab Jason Zemcik
April 11, 2022

Best Price and Copay Challenges: Frequently Asked Questions

11 Minute Read

Common manufacturer concerns on best price calculations, copay accumulators and maximizers, and 340B management as the effective date for the CMS Final Rule approaches.

Contracts & Pricing Brian Bumpus Matt Cunningham
March 28, 2022

Medicare Part B Sequestration Update

3 Minute Read

Regulatory Market Update Updates for Pharma Manufacturers As always, if you have questions on any of the content found in this or previous market updates, please reach out to...

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article